Techie News Service
10-04-2004, 06:00 AM
The problems with Vioxx, taken off the market last week, raise questions about the Food and Drug Administration's safety review process. Observers say longer clinical trials should be required.{br}{br}View the Entire Article (http://www.wired.com/news/medtech/0,1286,65205,00.html?tw=rss.TOP){br}